Copyright
©The Author(s) 2016.
World J Gastroenterol. Jun 14, 2016; 22(22): 5285-5292
Published online Jun 14, 2016. doi: 10.3748/wjg.v22.i22.5285
Published online Jun 14, 2016. doi: 10.3748/wjg.v22.i22.5285
Table 1 Overall characteristics of studies included in meta-analysis
| Ref. | Year | Patients characteristics | Study design | Outcome (SVR %) |
| Alqahtani et al[31] | 2015 | HCV mono-infected patients | a) SOF + RBV + PEG-IFN (n = 18) | a) 89% |
| TARGET cohort | b) SOF + RBV (n = 133) | b) 65% | ||
| Randomized by cirrhosis and previous treatment | ||||
| 50% Treatment naïve | ||||
| 51% Cirrhosis | ||||
| Chulanov et al[32] | 2014 | HCV mono-infected patients | a) SOF + RBV 16 wk (n = 30) | a) 87% |
| Russian multicenter cohort | b) SOF + RBV 24 wk (n = 31) | b) 90% | ||
| Randomized by cirrhosis | ||||
| 100% Treatment naïve | ||||
| 18% Cirrhosis | ||||
| Dalgard et al[33] | 2015 | HCV mono-infected patients | a) SOF + RBV + PEG-IFN 12 wk (n = 25) | a) 92% |
| Scandinavian cohort study | b) SOF + RBV 24 wk (n = 33) | b) 79% | ||
| 51% Treatment naïve | ||||
| 82% Cirrhosis | ||||
| Foster et al[17](BOSON) | 2015 | HCV mono-infected patients | a) SOF + RBV + PEG-IFN 12 wk (n = 181) | a) 93% |
| Randomized study | b) SOF + RBV 16 wk (n = 181) | b) 71% | ||
| 51% Treatment naïve | c) SOF + RBV 24 wk (n = 182) | c) 84% | ||
| 31% Cirrhosis | ||||
| Foster et al[27] | 2015 | HCV mono-infected patients | a) SOF + DCV 12 wk (n = 7) | a) 71% |
| NHS England Early Access Program | b) SOF + DCV + RBV 12 wk (n = 113) | b) 81% | ||
| 100% Decompensated Cirrhosis | c) SOF + LDV 12 wk (n = 7) | c) 57% | ||
| d) SOF + LDV + RBV 12 wk (n = 61) | d) 72% | |||
| Gane et al[29] (ELECTRON-2) | 2015 | HCV mono-infected patients | a) SOF + LDV 12 wk (n = 25) | a) 64% |
| Randomized study | b) SOF + LDV + RBV 12 wk (n = 26) | b) 100% | ||
| 50% Treatment naïve | c) SOF + LDV + RBV 12 wk (n = 50) | c) 82% | ||
| 32% Cirrhosis | ||||
| Hezode et al[34] | 2015 | HCV mono-infected patients | a) SOF + DCV 12 wk (n = 26) | a) 85% |
| French Compassionate Use Program | b) SOF + DCV + RBV 12 wk (n = 4) | b) 100% | ||
| 27% Treatment naïve | c) SOF + DCV 24 wk (n = 35) | c) 91% | ||
| 94% Cirrhosis | d) SOF + DCV + RBV 24 wk (n = 13) | d) 92% | ||
| Ingiliz et al[35] | 2015 | HCV-HIV co-infected patients | a) SOF + RBV + PEG-IFN 12 wk (n = 31) | a) 94% |
| German multicenter cohort study | b) SOF + RBV 24 wk (n = 23) | b) 91% | ||
| 50% Treatment naïve38% Cirrhosis | ||||
| Sulkowski et al[22](PHOTON) | 2014 | HCV-HIV co-infected patients | a) SOF + RBV 12 wk (n = 42) | a) 67% |
| International multicenter cohort | b) SOF + RBV 24 wk (n = 123) | b) 89% | ||
| 25% Treatment naïve | ||||
| Sulkowski et al[36] | 2014 | HCV mono-infected patients | a) SOF + DCV 24 wk (n = 13) | a) 92% |
| Randomized study | b) SOF + DCV + RBV 24 wk (n = 5) | b) 80% | ||
| 100% Treatment naïve | ||||
| 14% Cirrhosis | ||||
| Welzel et al[28] | 2015 | HCV mono-infected patients | a) SOF + DCV 24 wk (n = 11) | a) 100% |
| European Compassionate Use Program | b) SOF + DCV + RBV 24 wk (n = 13) | b) 85% | ||
| 72% Cirrhosis | ||||
| Zeuzem et al[37] (VALENCE) | 2014 | HCV mono-infected patients | a) SOF + RBV 12 wk (n = 11) | a) 27% |
| Randomized study | b) SOF + RBV 24 wk n = 250) | b) 84% | ||
| 41% Treatment naïve | ||||
| 24% Cirrhosis |
- Citation: Ampuero J, Reddy KR, Romero-Gomez M. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World J Gastroenterol 2016; 22(22): 5285-5292
- URL: https://www.wjgnet.com/1007-9327/full/v22/i22/5285.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i22.5285